Pharmaceutical Business Review
Return to: PBR Home
Top Headlines

Pharmaceutical Business Review

Almac to further expand Ireland campus with £30m investment Northern Ireland-based pharmaceutical firm Almac is investing £30m to further expand its European campus in Dundalk, Ireland to cope up with its existing and future client requirements in the European Union market. Production & Manufacturing > Manufacturing > News
ImmuPharma completes phase 3 trial of Lupus drug ImmuPharma has completed its 52-week, randomised, double-blinded, phase 3 clinical trial of Lupuzor, its lead candidate for the potential breakthrough compound for Lupus.
Contract Research & Services > Clinical Trials > News Almac to further expand Ireland campus with £30m investment By PBR Staff Writer
Northern Ireland-based pharmaceutical firm Almac is investing £30m to further expand its European campus in Dundalk, Ireland to cope up with its existing and future client requirements in the European Union market.
Production & Manufacturing > Manufacturing > News CGT Catapult enters into viral vector manufacturing technology collaboration with Freeline Therapeutics The Cell and Gene Therapy Catapult (CGT Catapult) has partnered with Freeline Therapeutics to further develop the company’s proprietary manufacturing platform at the CGT Catapult’s large scale GMP manufacturing centre in Stevenage, Hertfordshire, UK.
News
USPTO invalidates J&J’s patent on prostate cancer drug Zytiga By PBR Staff Writer
The US Patent & Trademark Office (USPTO) has invalidated a Johnson & Johnson (J&J) patent on prostate cancer drug Zytiga (abiraterone acetate).
Regulatory Affairs > News X-Chem, AstraZeneca expand drug discovery partnership X-Chem, a small molecule discovery specialist, has expanded its existing global drug discovery and technology transfer collaboration with AstraZeneca.
Drug Research > Drug Discovery & Development > News Carmot Therapeutics secures funding for type 2 diabetes drug Carmot Therapeutics, a biotechnology company, has closed a $15m financing to support the development of its type 2 diabetes drug, a dual GLP-1R/GIPR agonist, through early clinical proof of concept.
Drug Research > Drug Discovery & Development > News

Latest News and Insight by Sector

Production & Manufacturing

Almac to further expand Ireland campus with £30m investment
By PBR Staff Writer
Northern Ireland-based pharmaceutical firm Almac is investing £30m to further expand its European campus in Dundalk, Ireland to cope up with its existing and future client requirements in the European Union market.
Production & Manufacturing > Manufacturing > News
CGT Catapult to support CombiGene’s gene therapy for epilepsy
By PBR Staff Writer
Cell and Gene Therapy (CGT) Catapult and Sweden-based CombiGene have signed an agreement to develop manufacturing process for novel gene therapy to treat epilepsy.
Production & Manufacturing > Manufacturing > News

Drug Research

X-Chem, AstraZeneca expand drug discovery partnership
X-Chem, a small molecule discovery specialist, has expanded its existing global drug discovery and technology transfer collaboration with AstraZeneca.
Drug Research > Drug Discovery & Development > News
Carmot Therapeutics secures funding for type 2 diabetes drug
Carmot Therapeutics, a biotechnology company, has closed a $15m financing to support the development of its type 2 diabetes drug, a dual GLP-1R/GIPR agonist, through early clinical proof of concept.
Drug Research > Drug Discovery & Development > News

Inward Investment

New WuXi Life Science to acquire WuXi PharmaTech for $3.3bn
Shanghai-based WuXi PharmaTech has entered into a merger agreement with New WuXi Life Science and its wholly owned subsidiary WuXi Merger, worth a total cash consideration of $3.3bn.
Inward Investment > News
PPF Group acquires minority stake in Cytune Pharma
By PBR Staff Writer
PPF Group, in cooperation with SOTIO has completed acquisition of minority stake in French biotechnology firm Cytune Pharma.
Inward Investment > News

Packaging

Catalent completes acquisition of Australia's Pharmapak
By PBR Staff Writer
US-based Catalent Pharma Solutions has strengthened its ability to provide integrated solutions to customers with the acquisition of Pharmapak Technologies, an Australian pharmaceutical packaging business.
Production & Manufacturing > OTC > News
MP Global Products introduces foam-free packaging for shipment of temperature sensitive pharmaceuticals
MP Global Thermal Packaging Products insulated protective mailers and box liners are specifically designed for temperature control and protection of mail order shipments of temperature sensitive pharma, pet meds, and natural and organic cosmetics.
Packaging > News

Contract Research & Services

ImmuPharma completes phase 3 trial of Lupus drug
ImmuPharma has completed its 52-week, randomised, double-blinded, phase 3 clinical trial of Lupuzor, its lead candidate for the potential breakthrough compound for Lupus.
Contract Research & Services > Clinical Trials > News
Merck’s Keytruda regimen succeeds in phase 3 NSCLC trial
By PBR Staff Writer
Merck’s Keytruda (pembrolizumab) in combination with pemetrexed (Alimta) plus platinum chemotherapy has significantly improved overall survival (OS) and progression-free survival (PFS) of certain type of lung cancer patients in a phase 3 trial.
Contract Research & Services > Clinical Trials > News

Automation

Recursion Pharmaceuticals uses Splunk machine learning to treat genetic diseases
Biotechnology company Recursion Pharmaceuticals is using Splunk Enterprise and the Splunk Machine Learning Toolkit to reach its target of treating 100 molecular genetic diseases by 2025.
Automation > IT & Software > News
Broad Institute of MIT and Harvard joins discussions to create global CRISPR-Cas9 licensing pool
The Broad Institute of MIT and Harvard has joined discussions to form a non-exclusive CRISPR-Cas9 joint licensing pool coordinated by MPEG LA, an organization that operates patent pool licensing programs in various institutions and countries.
Automation > IT & Software > News

Regulatory Affairs

USPTO invalidates J&J’s patent on prostate cancer drug Zytiga
By PBR Staff Writer
The US Patent & Trademark Office (USPTO) has invalidated a Johnson & Johnson (J&J) patent on prostate cancer drug Zytiga (abiraterone acetate).
Regulatory Affairs > News
Novartis’ Kymriah nabs speedy reviews in US, Europe for lymphoma treatment
By PBR Staff Writer
Novartis’ CAR-T cell therapy Kymriah (tisagenlecleucel) has been granted fast-tracked reviews in the US and Europe for the treatment of relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
Regulatory Affairs > News



Data-Label.co.uk DataLabel have been supplying
the medical industry with labels
for over 10 years

Manufactures of
healthcare packaging
machinery